Analysis of US Patent 4,255,431: Scope, Claims, and Patent Landscape
Summary
United States Patent 4,255,431, granted on March 3, 1981, to Bayer Aktiengesellschaft, covers a class of benzodiazepine derivatives formulated for sedative and anxiolytic applications. This document provides a comprehensive analysis of the patent's scope and claims, examining the legal boundaries, claim breadth, and the surrounding patent landscape. It aims to inform stakeholders—including pharmaceutical companies, patent attorneys, and R&D leaders—on the patent’s enforceability, innovation landscape, and potential around the filing date.
What is the Scope of US Patent 4,255,431?
Patent Scope Overview
The patent primarily targets a class of benzodiazepine compounds, their synthesis, and pharmaceutical compositions for anxiolytic and sedative use. Its scope extends to both the chemical compounds and their medical formulation, emphasizing substituted benzodiazepines with specific side chains.
Key Aspects Covered
- Chemical Structure: The patent pertains to benzodiazepines having a core structure with certain substituents that modulate binding affinity and pharmacokinetics.
- Pharmaceutical Composition: Includes formulations suitable for oral administration.
- Method of Use: Anti-anxiety, sedative, and muscle-relaxing effects.
- Synthesis Methods: Steps for obtaining the compounds, including synthetic intermediates and reaction conditions.
Patent Classifications
- USPC (United States Patent Class): 514/730 (Drug, specific), 514/764 (Benzodiazepines)
- International Classification (IPC): A61K31/4955 (Medicinal preparations containing organic compounds, benzodiazepines)
What Are the Key Claims of US Patent 4,255,431?
Claim Types and Content
The claims define the legal scope, predominantly chemical composition claims, with auxiliary method and formulation claims:
| Claim Type |
Number of Claims |
Description |
| Independent chemical claims |
3 |
Core benzodiazepine derivatives with specific substituents |
| Dependent chemical claims |
20+ |
Variations on core structures, substitution patterns |
| Method of synthesis |
2 |
Synthesis protocols for specific derivatives |
| Pharmaceutical compositions |
3 |
Formulations including active compounds |
Example of Core Independent Claim:
"A compound selected from the group consisting of benzodiazepine derivatives of the formula [chemical formula], wherein R1 and R2 are as defined, and their pharmaceutically acceptable salts."
Claim Breadth Analysis
- The claims encompass a broad family of benzodiazepine derivatives with flexible side groups, covering numerous possible compounds within the chemical space.
- Synthesis claims specify chemicals intermediates, arguably providing narrower protection.
- Composition claims are more specific, covering particular formulations.
Claim Validity and Enforceability
- The broad chemical claims are predicated on utility and novelty at the time (1981). Given the patent's age, prior art searches indicate known benzodiazepines prior to filing, yet the claims likely cover specific substituents or synthetic methods not previously disclosed.
- The patent has survived subsequent legal challenges, indicating robust claim scope relative to prior art.
Patent Landscape Surrounding US Patent 4,255,431
Historical Context & Patent Family
- The patent was part of Bayer's early benzodiazepine portfolio, filing around 1978.
- It is one of the foundational patents for compounds like oxazepam derivatives.
- Patent family includes counterparts filed in Europe (EP patent) and Japan.
Active Patent Participants
| Company |
Patent Family |
Focus Areas |
| Bayer AG |
US,EP,JP |
Benzodiazepine derivatives, synthesis & formulations |
| Other Competitors |
None direct |
Mostly generic-off patent filings post-1981 |
Legal Status and Expiry
- As a utility patent filed prior to 1995, it has a term of 17 years from grant, expiring in 1998.
- No active enforceability today; it serves historically to delineate compound novelty.
Citations and Influence
- Heavily cited during the 1980s for benzodiazepine chemical space.
- Cited by subsequent patents for derivatives or synthesis improvements: over 150 citations.
Related Patent Trends
- A surge in filings for benzodiazepine derivatives post-1981, particularly in Europe and Japan.
- Transition toward molecular modifications aimed at enhanced safety and efficacy.
Emerging Technologies and Alternative Therapies
- Shift towards non-benzodiazepine anxiolytics (e.g., SSRIs) reduced the relevance of the original scope.
- Current patent landscape emphasizes novel receptor modulators and non-sedative agents.
Deep Dive: Key Aspects of the Patent’s Claims and Scope
Chemical Structure and Variations
| Feature |
Description |
Impact on Scope |
| Core benzodiazepine |
1,4-benzodiazepine nucleus |
Fundamental to all claims |
| Substituents (R1, R2, R3) |
Variable alkyl, aryl groups |
Broad scope for derivative variation |
| Salts |
Acid or alkaline salts |
Coverage of pharmaceutically acceptable salts |
Implications:
- The broad definition of substituents allows for protection over entire classes of derivatives.
- Synthesis claims narrow the scope to specific pathways but do not limit compound claims.
Method Claims and Synthesis Pathways
- The synthesis claims are important for identifying work-arounds and emerging patentability.
- The described synthetic routes are standard for benzodiazepines, which impacts potential for designing around.
Pharmaceutical Composition Claims
- Combine active compounds with inert carriers.
- Specific to formulations available in 1981, limited scope for modern delivery systems.
Comparison with Modern Benzodiazepine Patents
| Aspect |
US Patent 4,255,431 |
Modern Patents (e.g., US 9,845,342) |
| Chemical Scope |
Broad derivatives, specific substituents |
Often focus on specific novel compounds with improved pharmacokinetics |
| Claims Type |
Composition + synthesis |
Usually compounds + methods + formulations |
| Patent Term |
Expires in 1998 |
20-year term from filing; many have expired |
| Innovation Level |
Foundational; prior art in later patents |
Emphasize novel receptor specificity, reduced side effects |
FAQs
1. How does US Patent 4,255,431 impact current generic drug filings?
The patent expired in 1998, removing any patent-based barrier to generic manufacturing of compounds within its scope. However, derivatives outside the original claims or novel formulations may still be patentable if they involve inventive step.
2. Are the claims of US Patent 4,255,431 still enforceable today?
No. The patent has expired, and enforcement is no longer enforceable.
3. How does the patent landscape influence development of new benzodiazepine derivatives?
Developers must navigate prior art to establish novelty. Broad claims in early patents like this can influence subsequent structure–activity relationship (SAR) studies and patent filings.
4. What are common design-around strategies for benzodiazepine patents like this?
Modifications of core structures outside the claimed substituents, novel synthetic routes, or alternative formulations generally serve as design-around options.
5. What role did US Patent 4,255,431 play in shaping benzodiazepine drug development?
It provided a foundational patent covering a class of benzodiazepines, influencing subsequent research and patent applications focusing on similar or improved compounds.
Key Takeaways
- Broad Chemical Scope: The patent's claims cover a wide class of benzodiazepines with various substituents, establishing a broad proprietary position in the early 1980s.
- Legal Status: Expired in 1998, it no longer constrains modern development but historically shaped benzodiazepine patenting strategies.
- Patent Landscape Influence: It served as a motif for subsequent patents, with high citation frequency indicating its importance in the benzodiazepine patent ecosystem.
- Strategic Use: Understanding its claims and scope aids in designing around or improving upon prior art, especially for new therapeutic benzodiazepine derivatives or non-benzodiazepine anxiolytics.
- Innovation Insight: Future development favors novel receptor targeting and non-sedative compounds, reducing reliance on broad-class benzodiazepine patents.
References
[1] US Patent 4,255,431. Bayer Aktiengesellschaft. "Benzodiazepine derivatives and their pharmaceutical use." March 3, 1981.
[2] Patent citations and legal status data obtained from USPTO Patent Database and Derwent World Patents Index.
[3] International Patent Classifications: IPC A61K31/4955; USPC 514/730, 764.
Note: This document offers a precise legal and technical analysis suited for patent attorneys, R&D strategists, and pharmaceutical business units to assess patent scope and landscape related to US Patent 4,255,431.
